<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EN" hierarchy="1" humanitarian="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>GB-GOV-13-FUND--Newton-MR_R020957_1</iati-identifier>
  <reporting-org ref="10" type="DEPARTMENT OF BUSINESS, ENERGY AND INDUSTRIAL STRATEGY">
   <narrative xml:lang="EN">1</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Deep Mutational Scanning of Dengue Viruses for Vaccine Development</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">4</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">Emerging viral infections are a global threat to public health. Dengue is a mosquito-borne viral disease of common occurrence in most tropical and many subtropical areas. The only licensed vaccine available shows suboptimal protective efficacy especially for Dengue serotype 2. Consequently, vector control measures are the only widely used means of disease prevention and development of more potent and cross-reactive dengue vaccine would represent a major advance in disease control. Research to identify vaccines has been hampered by limitations of conventional approaches that cannot comprehensively search for useful viral mutations.    The current project aims to implement an approach that combines a novel massively parallel experimental technique and a virus construction technique developed in our lab to comprehensively test dengue virus mutants for their resistance to a host immune response.  This exercise will identify novel mutations that affect dengue resistance to a key antiviral pathway.  It will produce a collection of dengue mutants with varying degree of host resistance, enabling us to test different levels of viral attenuation which is critical for finding optimal immune responses for developing an effective vaccine.  Characterizations of these viruses by a battery of immunological and virological assays will give us an idea of the relationship between viral attenuation and the ensuing immune response, key information for fine tuning the efficacy of a dengue vaccine.  Future application of this exercise to investigate multiple interactions between virus and host immunity could accelerate our path to identify the elusive correlates of protection for dengue in humans.</narrative>
  </description>
  <other-identifier type="GB-GOV-13"></other-identifier>
  <activity-status code="2018-04-01"></activity-status>
  <activity-date iso-date="2018-04-30" type="2"></activity-date>
  <activity-date iso-date="2021-03-31" type="3"></activity-date>
  <activity-date iso-date="2021-04-29" type="4"></activity-date>
  <activity-date iso-date="TH" type="THAILAND"></activity-date>
  <contact-info type="UK RESEARCH &amp; INNOVATION">
   <organisation>
    <narrative xml:lang="EN">International Development</narrative>
   </organisation>
   <department>
    <narrative xml:lang="EN">Newton</narrative>
   </department>
   <person-name>
    <narrative xml:lang="EN">gcrf@ukri.org</narrative>
   </person-name>
   <email>https://www.ukri.org/</email>
   <website>Polaris House, Swindon, SN2 1LF</website>
   <mailing-address>
    <narrative xml:lang="EN">GBP</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="FAR EAST ASIA, REGIONAL" percentage="100">
   <narrative xml:lang="EN">789</narrative>
  </recipient-country>
  <recipient-region code="1" percentage="100" vocabulary="RESEARCH/SCIENTIFIC INSTITUTIONS"></recipient-region>
  <sector percentage="100" vocabulary="1">
   <narrative xml:lang="EN">43082</narrative>
  </sector>
  <collaboration-type code="10"></collaboration-type>
  <default-flow-type code="110"></default-flow-type>
  <default-finance-type code="D02"></default-finance-type>
  <default-aid-type code="5" vocabulary="1"></default-aid-type>
  <budget status="2" type="1">
   <period-start iso-date="2018-04-01"></period-start>
   <period-end iso-date="2018-03-31"></period-end>
   <value currency="GBP" value-date="2018-03-02">127676.56</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2019-04-01"></period-start>
   <period-end iso-date="2019-03-31"></period-end>
   <value currency="GBP" value-date="2018-03-02">128710.76</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2020-04-01"></period-start>
   <period-end iso-date="2020-03-31"></period-end>
   <value currency="GBP" value-date="2018-03-02">97314.96</value>
  </budget>
  <capital-spend percentage="1. Generation of a collection of dengue mutants with varying sensitivity to human STAT2.  2. Characterization of the immune response of dendritic cells following infection with the dengue mutants to gauge their potential as vaccine candidates."></capital-spend>
  <document-link format="HTTPS://WWW.UKRI.ORG/FUNDING/INFORMATION-FOR-AWARD-HOLDERS/GRANT-TERMS-AND-CONDITIONS/" url="A04">
   <title>
    <narrative xml:lang="EN">application/pdf</narrative>
   </title>
   <category code="0"></category>
  </document-link>
  <conditions attached="UK Research &amp; Innovation Grant Terms and Conditions"></conditions>
  <iati-activities>
   <iati-activity>
    <title>
     <narrative xml:lang="2021-09-24"></narrative>
    </title>
   </iati-activity>
  </iati-activities>
 </iati-activity>
</iati-activities>
